Genmab A/S announced transactions involving its shares made by managerial employees and their closely associated persons, as required by EU market abuse regulations. This disclosure ensures transparency about insider trading activities within the company. Genmab, a biotechnology firm focused on antibody medicines for cancer, continues to comply with regulatory standards while advancing its clinical pipeline. Investors can view these transactions as part of the company's commitment to openness and governance.
zSpace, Inc. has converted over $12 million of its outstanding debt into equity through agreements with two lenders, significantly improving its financial position. Fiza Investments converted about $10 million in debt into common and preferred stock ...
Nvidia unveiled new ARM-based hardware at Computex 2026, including the "Vera" CPU designed for AI and data centers. Jim Cramer praised the move, calling it a major positive for ARM Holdings, whose stock has surged over 200% this year. Nvidia is shift...
PMGC Holdings has entered a non-binding letter of intent to acquire a 76% controlling stake in a US-based precision machining company specializing in aerospace, space, defense, and semiconductor markets. The target company, with $5.46 million revenue...
Dividend 15 Split Corp. announced that the Toronto Stock Exchange has approved its Normal Course Issuer Bid (NCIB) to buy back up to 10% of its Preferred and Class A shares. The NCIB starts June 3, 2026, and runs through June 2, 2027, allowing the co...
Kinross Gold Corporation published its 2025 Sustainability Report showcasing its commitment to responsible mining through significant economic contributions of $4.9 billion to host countries and strong performance in environmental, social, and govern...
